市場調査レポート

商品コード

1401863

マラリアワクチンの2030年までの市場予測：薬剤別、ワクチンタイプ別、投与経路別、流通チャネル別、エンドユーザー別、地域別の世界分析

Malaria Vaccine Market Forecasts to 2030 - Global Analysis By Agent (Anopheles Species, Plasmodium Vivax, Plasmodium Falciparum and Other Agents), Vaccine Type, Route of Administration, Distribution Channel, End User and By Geography

出版日: 2023年12月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 595,815円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 753,742円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 911,669円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,076,775円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のマラリアワクチン市場は2023年に541億米ドルを占め、予測期間中のCAGRは31.6％で成長し、2030年には3,695億米ドルに達すると予測されています。

マラリアに対するワクチンは、蚊が媒介する感染症に対する防御を提供する医薬品です。マラリアウイルスを持つ雌のアノフェレス蚊に刺されると、マラリア原虫感染症と呼ばれる病気を媒介します。発汗、発熱、悪寒は、この慢性疾患の徴候です。これらのワクチンを投与するには、筋肉注射、皮下注射、皮内注射などいくつかの方法があります。

WHOによると、2019年には世界で約2億2,900万人のマラリア感染があり、40万9,000人が死亡しました。マラリアは主にアフリカ、アジア、中南米などの熱帯地域を苦しめてきました。

マラリアの高い発生率

マラリアは、特に熱帯・亜熱帯地域において、長年にわたり重大な健康懸念となっています。マラリアの流行には、気候変動、蚊や寄生虫の薬剤耐性、不十分な医療インフラ、社会経済的要因など、いくつかの要因が絡んでいます。しかし、有病率の上昇は、環境条件の変化や既存の予防戦略の有効性の変化によって起こる。これらの要因が市場の成長に寄与しています。

医療インフラの不足

医療のインフラが不十分なため、医療施設へのアクセスが制限され、ワクチンの入手が困難です。遠隔地には、予防接種を適切に保管・実施するためのクリニックや病院がないです。医療システムが不十分なため、保健教育や予防接種の啓発活動も制限されています。このような知識不足から、ワクチン接種率が低くなったり、ワクチン接種をためらったりすることがあります。これが市場拡大を阻害する要因となっています。

研究開発活動の増加

ワクチン接種のコスト、安全性、有効性の発展は、市場拡大に影響を与えます。公的と商業的な研究投資は、より新しく強力な予防接種の利用可能性に影響を与えます。さらに、特に資源が限られている環境では、政府や国際保健機関の支援が、マラリア予防接種の取り込みと普及に大きな影響を与える可能性があります。これらは市場の拡大に影響を与える変数です。

高い薬剤開発費

ワクチン開発の過程では、厳密な調査、臨床試験、規制手続きなどが必要となるため、多額の財政投資が必要となります。製造コストが高ければ、大量生産と流通の持続性に影響が出る。ワクチン接種を最も必要とする人々に届けるための長期的な努力も、それによって妨げられる可能性があります。製薬会社、政府、こうした取り組みを後援する組織は、法外な費用のために困難を抱えています。

COVID-19影響：

医療品、特にマラリアの予防と治療に必要な医療品の製造と供給は、COVID-19によってもたらされた世界のサプライチェーンの中断によって妨げられました。これは診断機器、抗マラリア薬、殺虫剤を散布した蚊帳の供給に影響を与えました。ロックダウン、渡航禁止、対面診療の制限など、すべてがマラリア予防接種の臨床研究を中断させる原因となった。その結果、試験、所見分析、規制当局の許可取得に遅れが生じています。

予測期間中、ハマダラカ種セグメントが最大となる見込み

予測期間中、ハマダラカ種セグメントが最大となる見込みです。マラリアの伝播は、ハマダラカ種に対するワクチン接種によって直接対処されます。マラリアの感染を広める蚊の能力を低下させることで、マラリアの感染をかなり遅らせることができます。マラリア原虫そのものに対するワクチン接種の研究は現在進行中であるが、ハマダラカ種に対するワクチンの開発によって、このような努力は助けられるであろう。

予測期間中、CAGRが最も高いのは筋肉内セグメントです。

予測期間中、CAGRが最も高くなると予想されるのは筋肉内セグメントです。医療専門家にとって、ワクチン接種を筋肉内で行うのはかなり単純なプロセスです。通常の注射手順以上の専門的な訓練は必要ないです。筋肉内に注射すると、特定の予防接種はより安定し、その効果をより効果的に維持できます。これは、冷蔵設備や医療サービスを容易に利用できない地域でよく見られる病気に対する予防接種では特に重要です。

最大のシェアを占める地域

予測期間中、北米が最大の市場シェアを占めると予測されています。この病気は広範囲に影響を及ぼすため、マラリア予防接種の開発・実施に向けた取り組みが世界的に行われています。北米大陸内のリスクは低下しているため、この地域では普遍的な予防接種よりも、マラリアが発生しやすい地域を訪れる人々に対する予防法に重点が置かれています。マラリアが流行している地域を訪れる人々にとって重要な対策は、蚊に刺されないようにすることと抗マラリア薬を使用することです。

CAGRが最も高い地域：

アジア太平洋は、マラリア感染者数の増加、人口の増加、疾病対策に対する政府の取り組みの増加により、予測期間中最も高いCAGRを維持すると予測されます。より強力なマラリアワクチンを開発するため、学術機関、製薬会社、国際保健機関は絶え間ない努力を続けています。有効性を高めるため、マラリア原虫のライフサイクルの様々な段階を対象とした代替ワクチン接種戦略に焦点を当てた研究も進行中です。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

企業プロファイル
- 追加市場参入企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

イントロダクション
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東とアフリカ

第11章主要発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第12章企業プロファイル

Taj Pharmaceuticals Limited
Sanofi
Actiza Pharmaceutical Private Limited
Ipca Laboratories Ltd.
Sumaya Biotech
Hikma Pharmaceuticals PLC
Bliss GVS Pharma Ltd.
Amneal Pharmaceuticals LLC
Strides Pharma Science Limited
VLP Therapeutics
Novartis AG
Pfizer Inc.
Mylan N.V.
Zydus Cadila
Cipla Inc.
Sun Pharmaceutical Industries Ltd.
Ipca Laboratories Ltd.
GeoVax

図表

List of Tables

Table 1 Global Malaria Vaccine Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
Table 3 Global Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
Table 4 Global Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
Table 5 Global Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
Table 6 Global Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
Table 7 Global Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 8 Global Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
Table 9 Global Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
Table 10 Global Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
Table 11 Global Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
Table 12 Global Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 12 Global Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 14 Global Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
Table 15 Global Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 16 Global Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 17 Global Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 18 Global Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 19 Global Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 20 Global Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 21 Global Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
Table 22 Global Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
Table 23 Global Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 24 Global Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
Table 25 Global Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
Table 26 North America Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
Table 27 North America Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
Table 28 North America Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
Table 29 North America Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
Table 30 North America Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
Table 31 North America Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
Table 32 North America Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 33 North America Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
Table 34 North America Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
Table 35 North America Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
Table 36 North America Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
Table 37 North America Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 38 North America Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 39 North America Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
Table 40 North America Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 41 North America Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 42 North America Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 43 North America Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 44 North America Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 45 North America Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 46 North America Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
Table 47 North America Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
Table 48 North America Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 49 North America Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
Table 50 North America Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
Table 51 Europe Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
Table 52 Europe Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
Table 53 Europe Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
Table 54 Europe Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
Table 55 Europe Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
Table 56 Europe Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
Table 57 Europe Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 58 Europe Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
Table 59 Europe Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
Table 60 Europe Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
Table 61 Europe Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
Table 62 Europe Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 63 Europe Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 64 Europe Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
Table 65 Europe Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 66 Europe Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 67 Europe Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 68 Europe Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 69 Europe Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 70 Europe Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 71 Europe Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
Table 72 Europe Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
Table 73 Europe Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 74 Europe Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
Table 75 Europe Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
Table 76 Asia Pacific Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
Table 77 Asia Pacific Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
Table 78 Asia Pacific Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
Table 79 Asia Pacific Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
Table 80 Asia Pacific Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
Table 81 Asia Pacific Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
Table 82 Asia Pacific Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 83 Asia Pacific Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
Table 84 Asia Pacific Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
Table 85 Asia Pacific Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
Table 86 Asia Pacific Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
Table 87 Asia Pacific Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 88 Asia Pacific Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 89 Asia Pacific Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
Table 90 Asia Pacific Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 91 Asia Pacific Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 92 Asia Pacific Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 93 Asia Pacific Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 94 Asia Pacific Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 95 Asia Pacific Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 96 Asia Pacific Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
Table 97 Asia Pacific Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
Table 98 Asia Pacific Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 99 Asia Pacific Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
Table 100 Asia Pacific Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
Table 101 South America Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
Table 102 South America Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
Table 103 South America Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
Table 104 South America Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
Table 105 South America Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
Table 106 South America Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
Table 107 South America Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 108 South America Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
Table 109 South America Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
Table 110 South America Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
Table 111 South America Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
Table 112 South America Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 113 South America Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 114 South America Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
Table 115 South America Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 116 South America Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 117 South America Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 118 South America Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 119 South America Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 120 South America Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 121 South America Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
Table 122 South America Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
Table 123 South America Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 124 South America Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
Table 125 South America Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
Table 126 Middle East & Africa Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
Table 127 Middle East & Africa Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
Table 128 Middle East & Africa Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
Table 129 Middle East & Africa Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
Table 130 Middle East & Africa Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
Table 131 Middle East & Africa Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
Table 132 Middle East & Africa Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
Table 133 Middle East & Africa Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
Table 134 Middle East & Africa Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
Table 135 Middle East & Africa Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
Table 136 Middle East & Africa Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
Table 137 Middle East & Africa Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 138 Middle East & Africa Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
Table 139 Middle East & Africa Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
Table 140 Middle East & Africa Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
Table 141 Middle East & Africa Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 142 Middle East & Africa Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 143 Middle East & Africa Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 144 Middle East & Africa Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 145 Middle East & Africa Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 146 Middle East & Africa Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
Table 147 Middle East & Africa Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
Table 148 Middle East & Africa Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 149 Middle East & Africa Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
Table 150 Middle East & Africa Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24383

According to Stratistics MRC, the Global Malaria Vaccine Market is accounted for $54.1 billion in 2023 and is expected to reach $369.5 billion by 2030 growing at a CAGR of 31.6% during the forecast period. Vaccines against malaria are medicines that offer protection against the infectious sickness carried by mosquitoes. The bite of a female Anopheles mosquito carrying the malaria virus transmits the disease, sometimes referred to as plasmodium infection. Sweating, fever, and chills are signs of this chronic illness. There are a few different ways to administer these vaccines: intramuscular, subcutaneous, and intradermal injections.

According to the WHO, there were around 229 million malaria infections and 409,000 fatalities worldwide in 2019. Malaria has primarily plagued tropical areas such as Africa, Asia, Central America, and South America.

Market Dynamics:

Driver:

High Incidence of malaria

Malaria has been a significant health concern for many years, particularly in tropical and subtropical regions. Several factors contribute to the prevalence of malaria, including climate change, drug resistance in mosquitoes and parasites, inadequate healthcare infrastructure, and socioeconomic factors. However, the rise in prevalence occurs due to changing environmental conditions or shifts in the effectiveness of existing prevention strategies. These factors contribute to the growth of the market.

Restraint:

Lack of healthcare infrastructure

People find it challenging to obtain vaccines due to restricted access to healthcare facilities resulting from inadequate infrastructure for healthcare. There aren't any clinics or hospitals in remote locations that are set up to properly store and give immunizations. Inadequate healthcare systems may also result in restricted availability of health education and immunization awareness initiatives. Low vaccination uptake and vaccine hesitancy may result from this lack of knowledge. This is the element impeding the market's expansion.

Opportunity:

Increase in the number of research and development activities

Developments in vaccination cost, safety, and effectiveness have an impact on market expansion. Public and commercial research investments have an impact on the availability of more recent and potent vaccinations. Furthermore, particularly in environments with limited resources, government and international health agency support can have a major influence on the uptake and dissemination of malaria vaccinations. These are the variables affecting the market's expansion.

Threat:

High cost of medication development

The process of developing a vaccine necessitates significant financial investments due to the rigorous research, clinical trials, and regulatory procedures involved. The sustainability of mass production and distribution is impacted if the cost of manufacturing is high. Long-term efforts to get the vaccination to people who need it most could be hampered by it. Pharmaceutical firms, governments, and organizations that sponsor these initiatives have difficulties because to the exorbitant expenses.

COVID-19 Impact:

The manufacture and delivery of medical goods, especially those required for the prevention and treatment of malaria, were hampered by the worldwide interruptions in supply chains brought about by COVID-19. This impacted the supply of diagnostic instruments, antimalarial medications, and bed nets sprayed with insecticide. Lockdowns, travel bans, and limits on face-to-face encounters all caused interruptions to clinical studies for malaria vaccinations. As a result, there has been a delay in testing, findings analysis, and gaining regulatory permissions.

The anopheles species segment is expected to be the largest during the forecast period

The anopheles species segment is expected to be the largest during the forecast period. The transmission of malaria is directly addressed by vaccination against the anopheles species. It may considerably slow the transmission of malaria by lessening the mosquito's capacity to disseminate the infection. Research on vaccinations against the malaria parasite itself is ongoing, however these efforts would be aided by the development of a vaccine against the anopheles species.

The intramuscular segment is expected to have the highest CAGR during the forecast period

The intramuscular segment is expected to have the highest CAGR during the forecast period. For medical experts, administering a vaccination intramuscularly is a rather simple process. Specialized training beyond normal injection procedures is not needed. When injected intramuscularly, certain vaccinations are more stable and maintain their effectiveness more effectively. This is particularly important for vaccinations against illnesses that are common in areas without easy access to refrigeration or healthcare services.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Due of the disease's extensive effects, efforts have been made globally to develop and implement malaria vaccinations. Because of the decreased risk within the continent, the focus in this region has mostly been on preventive methods for visitors to malaria-prone regions rather than universal immunization. The key tactics for people visiting areas where malaria is endemic continue to be preventing mosquito bites and using antimalarial drugs.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to the increasing number of malarial infections, rising population and increasing government initiative for disease control. To create more potent malaria vaccines, academic institutions, pharmaceutical firms, and international health organizations have been working nonstop. In an effort to increase effectiveness, some ongoing research focuses on alternate vaccination strategies that target various phases of the malaria parasite's lifecycle.

Key players in the market:

Some of the key players in Malaria Vaccine market include Taj Pharmaceuticals Limited, Sanofi, Actiza Pharmaceutical Private Limited, Ipca Laboratories Ltd., Sumaya Biotech, Hikma Pharmaceuticals PLC, Bliss GVS Pharma Ltd., Amneal Pharmaceuticals LLC, Strides Pharma Science Limited, VLP Therapeutics, Novartis AG, Pfizer Inc., Mylan N.V., Zydus Cadila, Cipla Inc., Sun Pharmaceutical Industries Ltd., Ipca Laboratories Ltd. and GeoVax.

Key Developments:

In February 2023, Sun Pharmaceutical Industries Ltd., one of India's leading pharmaceutical companies, has announced the acquisition of a 26.09% stake in Agatsa Software Pvt. Ltd. and a 27.39% stake in Remidio Innovative Solutions Pvt. Ltd., both of which are digital health startups.

In November 2022, Novartis and Medicines for Malaria Venture (MMV) have announced plans to advance a ganaplacide/lumefantrine- solid dispersion formulation (SDF) into a Phase III clinical trial to treat individuals with acute uncomplicated malaria caused by Plasmodium falciparum.

Agents Covered:

Anopheles Species
Plasmodium Vivax
Plasmodium Falciparum
Other Agents

Vaccine Types Covered:

Pre-Erythrocytic Vaccine
Erythrocytic Vaccine
Multi-antigen Vaccine
Other Vaccine Types

Route of Administrations Covered:

Intramuscular
Subcutaneous
Intradermal

Distribution Channels Covered:

Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Other Distribution Channels

End Users Covered:

Hospitals
Specialty Clinics
Homecare
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Malaria Vaccine Market, By Agent

5.1 Introduction
5.2 Anopheles Species
5.3 Plasmodium Vivax
5.4 Plasmodium Falciparum
5.5 Other Agents

6 Global Malaria Vaccine Market, By Vaccine Type

6.1 Introduction
6.2 Pre-Erythrocytic Vaccine
6.3 Erythrocytic Vaccine
6.4 Multi-antigen Vaccine
6.5 Other Vaccine Types

7 Global Malaria Vaccine Market, By Route of Administration

7.1 Introduction
7.2 Intramuscular
7.3 Subcutaneous
7.4 Intradermal

8 Global Malaria Vaccine Market, By Distribution Channel

8.1 Introduction
8.2 Retail Pharmacy
8.3 Online Pharmacy
8.4 Hospital Pharmacy
8.5 Other Distribution Channels

9 Global Malaria Vaccine Market, By End User

9.1 Introduction
9.2 Hospitals
9.3 Specialty Clinics
9.4 Homecare
9.5 Other End Users

10 Global Malaria Vaccine Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 Taj Pharmaceuticals Limited
12.2 Sanofi
12.3 Actiza Pharmaceutical Private Limited
12.4 Ipca Laboratories Ltd.
12.5 Sumaya Biotech
12.6 Hikma Pharmaceuticals PLC
12.7 Bliss GVS Pharma Ltd.
12.8 Amneal Pharmaceuticals LLC
12.9 Strides Pharma Science Limited
12.10 VLP Therapeutics
12.11 Novartis AG
12.12 Pfizer Inc.
12.13 Mylan N.V.
12.14 Zydus Cadila
12.15 Cipla Inc.
12.16 Sun Pharmaceutical Industries Ltd.
12.17 Ipca Laboratories Ltd.
12.18 GeoVax

マラリアワクチンの2030年までの市場予測：薬剤別、ワクチンタイプ別、投与経路別、流通チャネル別、エンドユーザー別、地域別の世界分析

Malaria Vaccine Market Forecasts to 2030 - Global Analysis By Agent (Anopheles Species, Plasmodium Vivax, Plasmodium Falciparum and Other Agents), Vaccine Type, Route of Administration, Distribution Channel, End User and By Geography

COVID-19影響：

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界のマラリアワクチン市場：薬剤別

第6章 世界のマラリアワクチン市場：ワクチンタイプ別

第7章 世界のマラリアワクチン市場：投与経路別

第8章 世界のマラリアワクチン市場：流通チャネル別

第9章 世界のマラリアワクチン市場：エンドユーザー別

第10章 世界のマラリアワクチン市場：地域別

第11章 主要発展

第12章 企業プロファイル